NASDAQ:MESO - Mesoblast Stock Price, Forecast & News

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

Mesoblast limited (NASDAQ:MESO) posted its quarterly earnings results on Monday, November, 25th. The company reported ($0.06) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.15) by $0.09. The business earned $17.05 million during the quarter, compared to the consensus estimate of $16.48 million. Mesoblast had a negative return on equity of 15.30% and a negative net margin of 342.39%. View Mesoblast's Earnings History.

Mesoblast is scheduled to release their next quarterly earnings announcement on Wednesday, February 19th 2020. View Earnings Estimates for Mesoblast.

6 equities research analysts have issued 12-month price targets for Mesoblast's stock. Their forecasts range from $6.00 to $23.00. On average, they anticipate Mesoblast's share price to reach $12.83 in the next twelve months. This suggests a possible upside of 20.7% from the stock's current price. View Analyst Price Targets for Mesoblast.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mesoblast.

News headlines about MESO stock have trended negative recently, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Mesoblast earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Mesoblast.

Some companies that are related to Mesoblast include Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Allogene Therapeutics (ALLO), Momenta Pharmaceuticals (MNTA), Acceleron Pharma (XLRN), Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Alector (ALEC), Regenxbio (RGNX), Cortexyme (CRTX) and SpringWorks Therapeutics (SWTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Exelixis (EXEL), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Gilead Sciences (GILD), InterDigital Wireless (IDCC), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Crispr Therapeutics (CRSP), NVIDIA (NVDA) and Progenics Pharmaceuticals (PGNX).

(MESO) raised $69 million in an IPO on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

Mesoblast's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Penbrook Management LLC (0.23%).

MESO stock was acquired by a variety of institutional investors in the last quarter, including Penbrook Management LLC.

Shares of MESO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MESO stock can currently be purchased for approximately $10.63.

Mesoblast has a market capitalization of $1.06 billion and generates $16.72 million in revenue each year. The company earns $-89,800,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Mesoblast employs 81 workers across the globe.View Additional Information About Mesoblast.

The official website for Mesoblast is http://www.mesoblast.com/.

Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The company can be reached via phone at 61-3-9639-6036 or via email at [email protected]